首页|Potentials of ribosomopathy gene as pharmaceutical targets for cancer treatment

Potentials of ribosomopathy gene as pharmaceutical targets for cancer treatment

扫码查看
原文链接
  • 国家科技期刊平台
  • NETL
  • NSTL
  • 万方数据
Ribosomopathies encompass a spectrum of disorders arising from impaired ribosome biogenesis and reduced functionality.Mutation or dysexpression of the genes that disturb any finely regulated steps of ribosome biogenesis can result in different types of ribosomopathies in clinic,collectively known as ribosomopathy genes.Emerging data suggest that ribosomopathy patients exhibit a significantly heightened susceptibility to cancer.Abnormal ribosome biogenesis and dysregulation of some ribo-somopathy genes have also been found to be intimately associated with cancer development.The cor-relation between ribosome biogenesis or ribosomopathy and the development of malignancies has been well established.This work aims to review the recent advances in the research of ribosomopathy genes among human cancers and meanwhile,to excavate the potential role of these genes,which have not or rarely been reported in cancer,in the disease development across cancers.We plan to establish a theoretical framework between the ribosomopathy gene and cancer development,to further facilitate the potential of these genes as diagnostic biomarker as well as pharmaceutical targets for cancer treatment.

Ribosome biogenesisRibosomopathy geneCancer treatment targetPharmaceutical target

Mengxin Wang、Stephen Vulcano、Changlu Xu、Renjian Xie、Weijie Peng、Jie Wang、Qiaojun Liu、Lee Jia、Zhi Li、Yumei Li

展开 >

Key Laboratory of Biomaterials and Biofabrication in Tissue Engineering of Jiangxi Province,Gannan Medical University,Ganzhou,Jiangxi,341000,China

School of Rehabilitation Medicine,Gannan Medical University,Ganzhou,Jiangxi,341000,China

Autoimmunity and Inflammation Program,HSS Research Institute,Hospital for Special Surgery New York,New York,NY,10021,USA

Division of Oral and Systemic Health Sciences,School of Dentistry,University of California,Los Angeles,CA,90095,USA

School of Medical Information Engineering,Gannon Medical University,Ganzhou,Jiangxi,341000,China

Inflammation and Immune Mediated Diseases Laboratory of Anhui Province,Anhui Institute of Innovative Drugs,Institute for Liver Diseases of Anhui Medical University,School of Pharmacy,Anhui Medical University,Hefei,230032,China

School of Basic Medicine,Gannan Medical University,Ganzhou,Jiangxi,341000,China

Institute of Oceanography,Minjiang University,Fuzhou 350108,China

展开 >

2024

10.1016/j.jpha.2023.10.001

药物分析学报(英文)
西安交通大学

药物分析学报(英文)

影响因子：0.244
ISSN：2095-1779
年,卷(期)：2024.14(3)